J&J Plots Five-Year Pharma Growth Plan Around Mega-Brands And Launches
Management outlined how the company plans to achieve above-market compound-annual growth from 2016 to 2021 during an R&D Day near its New Jersey headquarters.
You may also be interested in...
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.
Johnson & Johnson has written off a further $700m against the RSV asset that it obtained with its $1.75bn purchase of Alios.
Janssen is dropping the telomerase inhibitor as imetelstat nears the conclusion of Phase II in myelodysplastic syndrome and myelofibrosis, but Geron has $183m in cash on hand that it will use to take the drug forward on its own in one or both indications.